{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1116.3","meta":{"versionId":"4","lastUpdated":"2023-04-03T15:53:49.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"CancerLinQ Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2023-04-03"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.3","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1116.3"}],"version":"20150523","name":"RituximabAdminstration","title":"Rituximab Adminstration","status":"active","experimental":false,"date":"2015-05-23T01:00:02-04:00","publisher":"CancerLinQ Steward","description":"Indicates whether a patient has received rituximab administration","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.2"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.1"]}]},"expansion":{"identifier":"urn:uuid:0ead0b85-9821-4d7b-b6bf-8a934bae4fdb","timestamp":"2023-12-10T21:37:36-05:00","total":11,"contains":[{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20230901","code":"108809004","display":"Product containing rituximab (medicinal product)"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657862","display":"10 ML rituximab 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657867","display":"50 ML rituximab 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2105826","display":"10 ML rituximab-abbs 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2105834","display":"50 ML rituximab-abbs 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2273512","display":"10 ML rituximab-pvvr 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2273520","display":"50 ML rituximab-pvvr 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2472327","display":"10 ML rituximab-arrx 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2472335","display":"50 ML rituximab-arrx 10 MG/ML Injection"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20230901","code":"386919002","display":"Rituximab (substance)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20230901","code":"442108004","display":"Adverse reaction caused by rituximab administered by infusion (disorder)"}]}}